# OnCo record pt-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/pt-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "pt-1" ;
  schema:name "PT-1 (Primary Thrombocythaemia 1)"@en ;
  schema:description "PT-1 is the trial that made hydroxyurea the first-line drug in high-risk ET: anagrelide gave more arterial clots, more serious bleeding and more progression to myelofibrosis."@en ;
  schema:url <https://onco.cc/trials/pt-1/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://www.isrctn.com/ISRCTN72251782>, <https://www.nejm.org/doi/full/10.1056/NEJMoa043800> ;
  onco:status "positive" ;
  onco:tag "essential-thrombocythaemia", "mpn" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/essential-thrombocythaemia/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/anagrelide/>, <https://onco.cc/drugs/inca033989/>, <https://onco.cc/drugs/aspirin/> ;
  onco:companies <https://onco.cc/companies/mrc-ctu/> .